MedTrace Logo

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

NCT05577702 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2026-02-09

Study results available
· View outcomes & findings →

Summary

This study was conducted to evaluate the preliminary effectiveness and safety of treatment with tislelizumab alone and in combination with other investigational agents prior to surgery (neoadjuvant treatment) in adults with non-small cell lung cancer (NSCLC) that is able to be removed by surgery.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Ociperlimab

Administered as an intravenous infusion once every 3 weeks

DRUG

Alcestobart

Administered as an intravenous infusion once every 3 weeks

DRUG

Cisplatin

75 mg/m\^2 administered as an intravenous infusion once every 3 weeks

DRUG

Carboplatin

Administered as an intravenous infusion once every 3 weeks at an area under the curve (AUC) of 5 mg/mL/min

DRUG

Pemetrexed

500 mg/m\^2 administered as an intravenous infusion once every 3 weeks in participants with non-squamous NSCLC

DRUG

Paclitaxel

175 mg/m\^2 administered as an intravenous infusion once every 3 weeks in participants with squamous NSCLC

DRUG

Tislelizumab

Administered as an intravenous infusion once every 3 weeks

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Study Director · BeiGene

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-08
Primary Completion
2024-12-13
Completion
2025-01-23

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05577702 on ClinicalTrials.gov